New radiation schedule may cut treatment time for prostate cancer patients

NCT ID NCT03570827

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tested a shorter course of higher-dose radiation (hypofractionation) in 53 men with high-risk prostate cancer who had already had their prostate removed. The goal was to see if this approach could control cancer while reducing side effects. Participants also received hormone therapy. The study looked at how many men remained free of cancer recurrence or needed no further treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Hypofractionated radiation therapy and androgen suppression therapy
What this could lead to
If successful, this could offer a more convenient and potentially less toxic radiation schedule for men with high-risk prostate cancer after surgery.
What could go wrong
This is a small, single-arm phase II trial with only 53 participants, so results may not apply to all patients. Long-term side effects and cancer control rates are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.